Trials / Recruiting
RecruitingNCT03981003
Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,150 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Nīmes · Academic / Other
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease. In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Blood sample | 2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels |
Timeline
- Start date
- 2019-05-22
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
- First posted
- 2019-06-10
- Last updated
- 2024-05-14
Locations
28 sites across 2 countries: France, Martinique
Source: ClinicalTrials.gov record NCT03981003. Inclusion in this directory is not an endorsement.